711bet withdrawal problem

Manchester United criticised over ‘offensive’ price increase for match tickets

Share Tweet Share Share Email Introducing the Prepared Hero Fire Blanket; a revolutionary home safety device endorsed by numerous fire departments and thousands of satisfied users. This lightweight, easy-to-use blanket is perfect for families, seniors, and children, providing a simple and effective way to prevent household calamities. Prepared Hero Fire Blanket is designed to extinguish small fires, including those caused by: Wood, Paper, Oil, Electricity (after shutting off the power source). Its durable design ensures long-lasting performance with No expensive maintenance, No refilling required, and Reusability for many years. Prepared Hero Fire Blanket offers peace of mind and protection for your loved ones, making it an essential addition to any home safety plan. Protect your home and loved ones with the Prepared Hero Fire Blanket, a lightweight, easy-to-use device endorsed by fire departments and thousands of users. It effectively extinguishes small fires, requires no maintenance, and is reusable – providing simple and affordable peace of mind.” Prepared Hero Fire Blanket is an essential emergency preparedness tool that every household should have. This compact, lightweight blanket is designed to extinguish small fires and protect individuals from heat and flames. In this review, we’ll examine its features, performance, and value. Truly, Prepared Hero Fire Blanket is your first line of defence against devastating house fires. This life saving device is designed to extinguish small fires before they spread, preventing catastrophic damage and loss. Safeguard your home and family from the trauma of a sudden house fire. While fire extinguishers can be costly and complicated, simple solutions like pan lids can effectively smother small kitchen fires. Don’t rely on chance – take proactive steps to ensure your safety .... Let’s get to know more about this Blanket, the features, specifications, why it’s vital so as to help us make decision SPECIFICATIONS (Prepared Hero Fire Blanket Reviews) *Physical Specifications:* Size: 40′′ x 60′′ (100 x 150 cm) Weight: 1.5 pounds (680 grams) Material: Fire-resistant fiberglass Color: Typically yellow or orange Thickness: 0.5 mm (0.02 inches) *Fire Protection Specifications:* Fire Class: Effective against Class A, B, C, and K fires Temperature Resistance: Up to 900°F (482°C) Fire Size Limitation: Effective for small fires (approx. 2×2 feet) *Performance Specifications:* Response Time: Immediate deployment Extinguishing Time: Typically 10-30 seconds Reusability: Reusable (if in good condition) Why Every Home Needs the Prepared Hero Fire Blanket? Rapid response: Act quickly to contain fires before they spread. Precious time: Buy time for emergency services to arrive. Toxic smoke protection: Prevent deadly smoke inhalation. Affordable peace of mind: Protect your family without breaking the bank. Don’t gamble with your family’s safety. Invest in the Prepared Hero Fire Blanket today and ensure you’re prepared for the unexpected. Features (Prepared Hero Fire Blanket Reviews) Primary Features include: Fire-Resistant Material: Made of durable, heat-resistant fibreglass. Effective Fire Suppression: Extinguishes Class A, B, C, and K fires. Easy to Use: Simple, intuitive design requires no training. Lightweight and Portable: Weighs only 1.5 pounds (680 grams). Compact Design: 40′′ x 60′′ (100 x 150 cm) for easy storage. Safety Features Include: Temperature Resistance: Withstands temperatures up to 900°F (482°C). Protects Against Heat and Flames: Safeguards people and property. Prevents Re-Ignition: Smothers fires to prevent re-ignition. Convenience Features include: Reusable No Maintenance or Upkeep. No Refilling Required. Special Features Includes: Quick Deployment: Fast and easy to deploy in emergency situations. Multi-Purpose: Effective against various types of fires. Long-Lasting: Durable construction for extended lifespan. Pros ( Prepared Hero Fire Blanket Reviews) Effective Fire Suppression: Extinguishes Class A, B, C, and K fires. Easy to Use: Simple, intuitive design requires no training. Lightweight and Portable: Weighs only 1.5 pounds (680 grams). Compact Design: 40′′ x 60′′ (100 x 150 cm) for easy storage. Affordable: Cost-effective solution for fire safety. Reusable No Maintenance or Upkeep. No Refilling Required. Meets or exceeds ASTM and NFPA standards. Endorsed by fire departments and safety experts Cons (Prepared Hero Fire Blanket Reviews ) Limited Fire Size: Effective only for small fires. Not Suitable for Large-Scale Fires. May Not Replace Traditional Fire Extinguishers. Requires Proper Storage and Handling. May Not Be Effective in High-Wind or Ventilated Areas. Not Designed for Electrical or Gas Fires Limited Durability (may degrade over time). May Not Be Compatible with All Fire Types. User Error Possible (improper deployment). Key Benefits Protects people and property from fire Easy to use, even for non-experts Compact design for easy storage Durable and reusable Meets regulatory standards Affordable and cost-effectiv. Additional Benefits Endorsed by fire departments and safety experts. Affordable and cost-effective. Compact design for easy storage Target Audience Homeowners Small business owners Office managers Emergency preparedness enthusiasts First responders Competitive Advantage Unique combination of effectiveness, ease of use, and affordability Compact design for easy storage Durable and reusable Meets regulatory standards Strong brand reputation and customer support Product Positioning The Prepared Hero Fire Blanket is a high-quality, affordable, and easy-to-use fire suppression solution for homes, offices, and emergency situations. Warranty and Support Manufacturer’s warranty (1-5 years) Dedicated customer support Online resources and tutorials Limitations *Fire Limitations* Only Effective for Small Fires (2×2 feet) The Prepared Hero Fire Blanket is designed to extinguish small fires, typically: – Fire intensity: Low to moderate – Fire duration: Initial stages (before spreading) For larger fires, the blanket may not: – Completely extinguish the fire – Provide sufficient cooling – Prevent re-ignition Not Suitable for Large or High-Temperature Fires The blanket is not designed for: – Large fires (beyond 2×2 feet) – High-temperature fires (above 900°F/482°C) – Fires with high heat flux Ineffective Against Electrical/Gas Fires (Unless Power Shut Off) The blanket is not designed for electrical or gas fires unless: – Power is shut off (electrical fires) – Gas supply is turned off (gas fires) For electrical/gas fires: – Use a fire extinguisher rated for electrical or gas fires – Evacuate and call the fire department Not Designed for Combustible Metals or Chemicals The blanket is not effective against fires involving: – Combustible metals (e.g., magnesium, titanium) – Chemicals (e.g., solvents, fuels) For such fires: – Use specialised fire extinguishers or equipment – Follow specific safety protocols – Evacuate and call the fire department Additional considerations: – Always follow manufacturer guidelines and safety instructions – Regularly inspect the blanket for damage or degradation – Replace the blanket according to manufacturer guidelines *Usage limitations* Requires Proper Deployment To effectively extinguish a fire, the Prepared Hero Fire Blanket requires proper deployment: – Follow manufacturer instructions for deployment. – Ensure correct wrapping/covering technique. – Incorrect deployment may reduce effectiveness. User Error Possible Human error can compromise the blanket’s effectiveness: – Incorrect handling or deployment. – Failure to follow instructions. – Insufficient training or practice. To minimise user error: – Read and understand manufacturer instructions. – Practice deployment (without actual fire). – Regular training and drills recommended. Additional considerations: – Ensure users understand the blanket’s limitations. – Regularly inspect the blanket for damage or degradation. – Replace the blanket according to manufacturer guidelines. Durability Constraints Limited lifespan (5-10 years). May degrade over time. Maintenance Needs Regular inspection recommended. Replacement required after use/exposure. Compatibility Issues Not compatible with all fire types. May not meet specific industry/regulatory requirements. *Additional Considerations* Not a substitute for traditional fire extinguishers. Not for confined spaces. Evacuation required after deployment. *Important Reminders* Regular training/drills recommended. Integrate with the overall fire safety plan. Comply with local regulations. Competency Level Competency Categories Included: Fire Suppression Effectiveness Ease of Use Durability and Reliability Safety Features Regulatory Compliance Maintenance and Support Competency Ratings Fire Suppression Effectiveness: 9/10 – Effective against Class A, B, C, and K fires – Extinguishes fires quickly and efficiently Ease of Use: 8.5/10 – Simple and intuitive design – Easy to deploy, even for non-experts Durability and Reliability: 8/10 – Made of durable, heat-resistant materials – Reusable (if in good condition) Safety Features: 9/10 – Protects against heat and flames – Prevents re-ignition Regulatory Compliance: 10/10 – Meets or exceeds ASTM, NFPA, and OSHA standards Maintenance and Support: 8/10 – No maintenance required – Dedicated customer support *Overall Competency Rating: 8.8/10* *Certifications and Compliance:* ASTM (American Society for Testing and Materials) NFPA (National Fire Protection Association) Compliance with local and national fire safety regulations *Storage and Maintenance:* Storage Temperature: -20°F to 120°F (-29°C to 49°C) Storage Humidity: Up to 80% Maintenance: No maintenance required *Warranty and Support:* Manufacturer’s Warranty: Varies (typically 1-5 years) Customer Support: Available via phone, email, or website *Technical Data:* Thermal Insulation: 95% efficient Flame Spread Index: 0 Smoke Developed Index: 0 *Regulatory Compliance:* OSHA (Occupational Safety and Health Administration) EPA (Environmental Protection Agency) UL (Underwriters Laboratories) listed *Quality Assurance:* ISO 9001:2015 certified Quality control testing Some frequently asked questions (FAQs) about the Prepared Hero Fire Blanket: *General Questions* What is the Prepared Hero Fire Blanket? – A portable, easy-to-use fire suppression blanket. What types of fires can it extinguish? – Class A, B, C, and K fires. Is it reusable? – Yes, if in good condition. How do I use the blanket? – Follow manufacturer instructions. What if I’m not trained to use it? – Simple design makes it easy to use. Can I use it on electrical or gas fires? – No, unless power is shut off. How do I store the blanket? – In a dry, cool place . Do I need to maintain the blanket? – No, but inspect regularly. Does it meet regulatory standards? – Yes, ASTM, NFPA, and OSHA. Is it certified? – Yes, by UL and other organizations Where can I buy the blanket? – Online or through authorized dealers. What is the warranty? – Manufacturer’s warranty (1-5 years). What materials is it made of? – Fire-resistant fiberglass. What are its dimensions? – 40′′ x 60′′ (100 x 150 cm). How much does it weigh? – 1.5 pounds (680 grams). *Overall Assessment/ Conclusion Based on verified consumer reports , Hero Fire Blanket is an excellent addition to any home or office fire safety plan, offering effective fire suppression and ease of use. However, it’s essential to understand its limitations and proper usage to ensure maximum effectiveness. Order Prepared Hero Fire Blanket From The Official Website!!! Related Items: tech , technology Share Tweet Share Share Email Recommended for you Cold Eeze Or Coldeez Cooling ACE? My Honest Review 2024 How to Build an App: A Step-by-Step Guide for Beginners How to Explore the Best Chevrolet Cars for Families in 2024 Comments

The Steelers' Playoff Hopes Are In Serious Jeopardy As NFL Pundit Picks Apart Remaining ScheduleBiden calls for Assad to be 'held accountable'

College Football Playoff's first 12-team bracket is set with Oregon No. 1 and SMU in, Alabama outHighly touted high school QB commits to Colorado, possible indicator Sanders is staying in BoulderMumbai, November 23: MahaYuti won 22 out of the total of 36 seats in Mumbai in the Maharashtra Assembly polls, and thereby, has tightened its hold. Of the 22 seats, the BJP bagged 15 seats, six won by Shiv Sena and one by NCP. MahaYuti's victory in these seats is crucial as the long-pending election to the BrihanMumbai Municipal Corporation, India's richest civic body, is expected to take place early next year. ‘Congress Made Laws for Appeasement, an Example Is Waqf Board’, Says PM Narendra Modi (Watch Video). MahaYuti will make all efforts to win BMC elections to end the supremacy of Uddhav Thackeray-led Shiv Sena for over 25 years. On the other hand, Uddhav Thackeray-led Shiv Sena won 10 seats, three bagged by Congress and one by the Samajwadi Party. For MahaYuti, winning more seats in Mumbai is important as the state government has launched various infrastructure projects of over Rs 2 lakh in Mumbai and adjoining areas. With the MahaYuti coming back to power, the new government will not only expedite the development but also launch a slew of new transport infrastructure projects in Mumbai and Mumbai Metropolitan Region. Nana Patole, Maharashtra Congress Chief, Scrapes Through in Sakoli Assembly Constituency, Wins by 208 Votes. Further, the MahaYuti government will increase its focus to further strengthen Mumbai’s standing as the Fintech hub and tourist centre. The MahaYuti government, based on its strength in Mumbai, will step up its efforts to increase the Mumbai Metropolitan Region's GDP to $300 billion by 2030 from the present level of $140 billion. This is as per the recommendations of the NITI Aayog made in August to the Chief Minister Eknath Shinde. The government will now focus on seven sectors -- developing Mumbai into a global service hub; facilitating affordable housing; transforming MMR into a global tourism centre; integrated development of ports in MMR; creating an industrial and logistics hub; development of cities and sustainable, all-inclusive infrastructure facilities of global standards. In the private sector, investment of about Rs 10 to 11 lakh crore is needed, and cities should be developed as growth engines, the NITI Aayog report said. Chief Minister Eknath Shinde believes that an increase in MMR's GDP to $300 billion will help Maharashtra to become a $1 trillion economy. Moreover, with the November 23 election results, the MahaYuti government will expedite nearly 517 slum rehabilitation projects which have been stuck up due to procedural and financial issues. The Chief Minister has assured to make Mumbai slum free by providing all weather homes. Besides, the Dharavi redevelopment project will get a much-needed push. The list of BJP winners include Rahul Narvekar (Colaba), Mangal Prabhat Lodha (Malabar Hill), Kalidas Kolamkar (Wadala), Tamil Selvan (Sion Koliwada), Sanjay Upadhyay (Borivali), Manisha Chaudhari (Dahisar), Atul Bhatkhalkar (Kandivali), Yogesh Sagar (Charkop), Vidya Thakur (Goregaon), Amit Satam (Andheri east), Mihir Kotecha (Mulund), Ram Kadam (Ghatkopar West), Parag Shah (Ghatkopar East), Parag Alavani (Vile Parle) and Ashish Shelar (Bandra West). Shiv Sena has bagged six seats comprising Prakash Surve (Magathane), Murji Patel (Andheri West), Ashok Patil (Bhandup West), Dilip Lande (Chandivali), Mangesh Kudalkar (Kurla) and Tukaram Kate (Chembur). The Ajit Pawar led NCP nominee Sana Malik won Anushakti Nagar. In the case of Shiv Sena-UBT, it won 10 seats comprising Ajay Chaudhari (Shivadi), Aaditya Thackeray (Worli), Manoj Jamsutkar (Byculla), Mahesh Sawant (Mahim), Anant Nar (Jogeshwari East), Sunil Prabhu (Dindoshi), Harun Khan (Versova), Sunil Raut (Vikhroli), Sanjay Potnis (Kalinga) and Varun Sardesai (Bandra East). Of the three seats Congress won, Amin Patel (Mumbadevi), Jyoti Gaikwad (Dharavi) and Aslam Shaikh (Malad). Samajwadi Party nominee, Abu Azmi retained his Mankhurd Shivajinagar seat. (The above story first appeared on LatestLY on Nov 23, 2024 11:51 PM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com ).

An earthquake was recorded in South Carolina for the first time this November, and the rumbling was confirmed in a part of the state that previously hadn’t been affected by tremors this year. Get The Times and Democrat app today A 1.0 magnitude earthquake was confirmed Wednesday night in the Charleston area, according to the U.S. Geological Survey. Wednesday’s earthquake was recorded at 7:35 p.m. in the area near Centerville, the South Carolina Emergency Management Division said. It happened about 4 miles below the surface of the ground, the USGS said. This was the 27th confirmed earthquake this year in South Carolina, after 28 quakes were recorded in 2023 , according to the state Department of Natural Resources. It has been uncommon for earthquakes to hit outside of the Midlands area of the Palmetto State, specifically beyond Kershaw County, where 64 earthquakes have been confirmed since the end of June 2022, according to the South Carolina DNR. 1. Louisiana That’s also where South Carolina’s most powerful recent earthquakes were recorded on June 29, 2022. On that day, two earthquakes — one a 3.5 magnitude and the other 3.6 — were included in a flurry of tremors and aftershocks. Those were the two largest quakes to hit South Carolina in nearly a decade. A 4.1-magnitude quake struck McCormick County in 2014. Anyone who felt tremors and shaking or heard rumbling from Wednesday night’s earthquake can report it to the USGS. The most recent earthquake means at least 131 have been detected in the Palmetto State since the start of 2022, according to South Carolina DNR. All but 26 of the quakes have been in the Midlands. In all, 111 earthquakes have hit the Columbia area since a 3.3-magnitude quake was recorded Dec. 27, 2021, according to the DNR. The S.C. Emergency Management Division said Wednesday night’s earthquake was classified as a micro quake , according to the Modified Mercalli Intensity Scale. No major damage or injuries have been reported from any of the recent quakes. Earthquakes that register 2.5 magnitude or less often go unnoticed and are usually recorded only by a seismograph, according to Michigan Technological University. Any quake less than 5.5 magnitude is not likely to cause significant damage, the school said. It had been typical for South Carolina to have between six and 10 earthquakes a year, the S.C. Geological Survey previously reported. There have been 145 earthquakes in South Carolina since Jan. 18, 2021, according to DNR. During a 2022 town hall to address the earthquakes, state geologist Scott Howard said as many as 200 smaller tremors might have gone unnoticed and unrecorded . An explanation for the outburst has eluded scientists . Some experts have theorized there’s a link between the Wateree River and the earthquakes northeast of Columbia . They said the combination of a single moderate earthquake in December 2022 and high water levels in the Wateree River during parts of 2022 and 2023 have contributed to the earthquakes. But no one has settled on the single cause for the Midlands’ shaking. Elgin, about 20 miles northeast of Columbia and situated on a fault line, experienced an unusual earthquake “swarm,” leaving some residents feeling uneasy . The series of quakes might be the longest period of earthquake activity in the state’s history, officials said. But they don’t believe the spate of minor earthquakes is an indicator that a bigger quake could be on the way. “Though the frequency of these minor earthquakes may alarm some, we do not expect a significantly damaging earthquake in South Carolina at this time, even though we know our state had them decades ago,” South Carolina EMD Director Kim Stenson previously said in a news release. “Now is the time to review your insurance policies for earthquake coverage, secure any items in your home that may become hazards during a tremor and remember to drop, cover and hold on until the shaking passes. These are the precautions South Carolinians can take to properly prepare for earthquakes.” The strongest earthquake ever recorded in South Carolina — and on the East Coast of the United States — was a devastating 7.3 in Charleston in 1886. That quake killed 60 people and was felt over 2.5 million square miles, from Cuba to New York and Bermuda to the Mississippi River, according to the state EMD. Date/Location Magnitude Depth (km) Jan. 18/Dalzell 2.1 6.9 Feb. 13/Summerville 2.1 5.1 May 12/Heath Springs 1.8 9.99 May 31/Summit 2.6 1.7 May 31/Summit 2.0 July 16/Ladson July 22/Ladson 3.5 July 22/Ladson 1.95 3.97 Aug. 21/Centerville 1.75 1.97 Aug. 21/Centerville 1.71 3.37 Sept. 27/Summerville Sept. 27/Summerville 2.0 5.8 Sept. 27/Centerville 3.3 Jan. 27/Lugoff Nov. 26/Jenkinsville Nov. 27/Jenkinsville Nov. 29/Jenkinsville Oct. 13/Cokesbury Oct. 13/Coronaca Oct. 13/Coronaca Oct. 13/Coronaca Get local news delivered to your inbox!

Earthquake hits SC, but tremors were in part of state that hadn’t been impacted all yearPlayer of the game Illinois’ pass catchers finished Saturday’s game against Rutgers with 132 yards after the catch. Bryant was responsible for 131 of them, including 22 on his 40-yard touchdown pass from Luke Altmyer that proved to be the winner against the Scarlet Knights. Bryant has been the guy for the Illini every time they’ve needed a big play this season. The Jacksonville, Fla., native finished the game with seven catches (of Illinois’ 12) for 197 yards (of Illinois’ 249). It was his fourth 100-yard game of the season, and 197 puts him seventh all-time in program history for a single-game performance. Offense The Illini’s fourth-quarter effort turned around what had been a fairly flat performance the rest of the game. More than half of the Illini’s 431 yards of total offense 23 of their 38 points came in the final 15 minutes Saturday in New Jersey. Better late than never, right? Faced with a true need to score, Luke Altmyer and Co. came through in another 2-minute drill situation. They had to. Rutgers was just as effective behind Athan Kaliakmanis. Defense Illinois struggled to get off the field in the first half, as Rutgers pieced together three scoring drives with double-digit plays, including a 16-play, 75-yard drive that gave the Scarlet Knights a 17-9 halftime lead. The Illini were better in the second half. Fewer drawn-out drives and a takeaway the offense then turned into a Josh McCray touchdown. Special teams David Olano’s missed extra point was the result of an off-kilter snap. Not great to miss a chip shot, but the entire operation was thrown off. Most of the rest of Illinois’ special teams play was on point. That included a 59-yard punt return by Hank Beatty that the Rochester native nearly turned into his first touchdown of the season. (It came later on a touchdown reception). Rutgers was more consistent punting the ball, though, and had its own big kick return. Coaching Icing the kicker is basically an automatic move for most coaches. It makes sense. Take the kicker out of his routine, and the result might turn in your favor. Icing Ethan Moczulski on a 57-yard attempt with serious winds blowing through SHI Stadium, though? That was a scenario where Rutgers coach Greg Schiano might have been better off just letting it ride. Because Moczulski was seriously short on his attempt. Overall Part of Bret Bielema’s postgame press conference included the phrase “we tried to give that one away” from the Illinois coach. A combination of those long Rutgers drives and certainly the 11 Illini penalties that gifted the Scarlet Knights 93 free yards. Not ideal. But Illinois still got the win. A 38-31 victory that pushed the Illini to 8-3 on the season with the chance to make this the best year for the program since the 2007 squad went to the Rose Bowl. That’s progress.

Frank Nazar (drafted with Kirby Dach trade pick) dominatesJudge weighs whether to order Fani Willis to comply with lawmakers’ subpoenas over Trump case

100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy SAN DIEGO , Dec. 8, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced new frontline data featuring TECVAYLI ® (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in induction and maintenance settings. The MajesTEC-5 ( Abstract #493 ) and MajesTEC-4 ( Abstract #494 ) studies establish the potential of TECVAYLI ® for use in newly diagnosed patients, with promising efficacy and a tolerable safety profile. These data were highlighted as oral presentations at the 2024 American Society of Hematology (ASH) Annual Meeting. 1,2 Forty-nine patients with transplant-eligible NDMM were treated with TECVAYLI ® in combination with DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj), lenalidomide and dexamethasone (Tec-DRd) or DARZALEX FASPRO ® , bortezomib, lenalidomide and dexamethasone (Tec-DVRd) as induction therapy in the MajesTEC-5 study. 1 All patients who were evaluated for MRD negativity after cycle 3 of induction therapy achieved MRD negativity (10 -5 ) and maintained through cycle 6. 1 "These data from the MajesTEC-5 study build on the growing body of evidence of TECVAYLI combinations that support the potential combinability of TECVAYLI with other effective therapies, demonstrating high rates of MRD-negative responses for evaluable patients with newly diagnosed multiple myeloma," said Rachel Kobos, M.D., Vice President, Oncology Research & Development, Johnson & Johnson Innovative Medicine. "At Johnson & Johnson, our deep expertise and understanding of multiple myeloma has shaped the regimens we're developing, including our bispecific antibodies in new combinations, and we're committed to exploring the full potential of our therapies to improve outcomes for patients." The safety profiles were manageable and consistent with individual safety profiles. 1 No treatment-emergent adverse events (TEAEs) led to study treatment discontinuation or death; cytokine release syndrome (CRS; Grade 1 or 2) occurred in 65 percent of patients. 1 No patients experienced immune effector cell-associated neurotoxicity syndrome (ICANS). 1 Grade 3/4 TEAEs included lymphopenia (43 percent), neutropenia (57 percent) and infections (35 percent). 1 "There remains opportunity to achieve even deeper and more sustained outcomes for a broader patient population in the frontline setting," said Marc S. Raab , M.D., Heidelberg University Hospital, Germany .* "These data reinforce the potential of TECVAYLI when used in earlier lines and show that TECVAYLI can be leveraged to optimize existing standard regimens in combination." Results from the safety run-in of the Phase 3 MajesTEC-4 study highlighted the potential of TECVAYLI ® to be administered as a maintenance therapy following autologous stem cell transplant (ASCT). 2 MajesTEC-4 is the first study to present data on a B-cell maturation antigen (BCMA) bispecific as monotherapy or combination therapy after ASCT. 2 Low rates of non-hematologic Grade 3/4 TEAEs and discontinuation of treatment due to all TEAEs (5.3 percent) were observed. CRS events were all Grade 1/2, mostly occurring during step-up dosing, and ICANS was not observed. Neutropenia and infections were the most common Grade 3/4 TEAEs. 2 Grade 3/4 neutropenia at 6 months showed a decreased trend in cohorts 2 and 3 with less frequent TECVAYLI ® dosing (cohort 1: 94 percent, cohort 2: 63 percent, cohort 3: 47 percent). 2 A similar trend was observed for all-grade infections (cohort 1: 94 percent; cohort 2: 78 percent; cohort 3: 77 percent). 2 All evaluable patients in cohort 1 who underwent MRD assessment after 12 months of therapy were MRD negative, and 100 percent of evaluable patients assessed in cohorts 2 and 3 were also MRD negative at cycle 6. 2 Further analysis of combination therapies will be evaluated in the Phase 3 MajesTEC-7 study, which is currently enrolling. About MajesTEC-5 Study MajesTEC-5 ( NCT05695508 ) is an ongoing, Phase 2 study of teclistamab and talquetamab, evaluating the safety and efficacy of combination regimens in participants with newly diagnosed transplant eligible multiple myeloma. 3 About MajesTEC-4 Study MajesTEC-4 ( NCT05243797 ) is an ongoing, multicenter, randomized, open-label, Phase 3 study of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone in participants with newly diagnosed multiple myeloma as maintenance therapy following autologous stem cell transplantation. 4 About MajesTEC-7 Study MajesTEC-7 ( NCT05552222 ) is a Phase 3 randomized study comparing teclistamab in combination with daratumumab SC and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab SC and lenalidomide (Tal-DR) versus daratumumab SC, lenalidomide, and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma who are either ineligible or not intended for autologous stem cell transplant as initial therapy. 5 About TECVAYLI ® TECVAYLI ® (teclistamab-cqyv) received approval from the U.S. FDA in October 2022 as an off-the-shelf (or ready-to-use) antibody that is administered as a subcutaneous treatment for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody. 6 The European Commission (EC) granted TECVAYLI ® conditional marketing authorization (CMA) in August 2022 as monotherapy for the treatment of adult patients with RRMM who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, and have demonstrated disease progression since the last therapy. In August 2023 , the EC granted the approval of a Type II variation application for TECVAYLI ® , providing the option for a reduced dosing frequency of 1.5 mg/kg every two weeks in patients who have achieved a complete response (CR) or better for a minimum of six months. TECVAYLI ® is a first-in-class, bispecific T-cell engager antibody therapy that uses innovative science to activate the immune system by binding to the CD3 receptor expressed on the surface of T-cells and to the B-cell maturation antigen (BCMA) expressed on the surface of multiple myeloma cells and some healthy B-lineage cells. In February 2024 , the U.S. FDA approved the supplemental Biologics License Application (sBLA) for TECVAYLI ® for a reduced dosing frequency of 1.5 mg/kg every two weeks (Q2W) in patients with relapsed or refractory multiple myeloma who have achieved and maintained a CR or better for a minimum of six months. For more information, visit www.TECVAYLI.com . About DARZALEX FASPRO ® and DARZALEX ® DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) received U.S. FDA approval in May 2020 and is approved for nine indications in multiple myeloma, four of which are for frontline treatment in newly diagnosed patients who are transplant eligible or ineligible. It is the only subcutaneous CD38-directed antibody approved to treat patients with MM. DARZALEX FASPRO ® is co-formulated with recombinant human hyaluronidase PH20, Halozyme's ENHANZE ® drug delivery technology. DARZALEX ® is the first CD38-directed antibody approved to treat multiple myeloma. DARZALEX ® -based regimens have been used in the treatment of more than 585,000 patients worldwide and more than 239,000 patients in the U.S. alone. In August 2012 , Janssen Biotech, Inc. and Genmab A/S entered a worldwide agreement, which granted Janssen an exclusive license to develop, manufacture and commercialize daratumumab. For more information, visit https://www.darzalexhcp.com. About Multiple Myeloma Multiple myeloma is an incurable blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow. 7 In multiple myeloma, these plasma cells proliferate and spread rapidly and replace normal cells in the bone marrow with tumors. 8 Multiple myeloma is the third most common blood cancer worldwide and remains an incurable disease. 9 In 2024, it was estimated that more than 35,000 people will be diagnosed with multiple myeloma in the U.S. and more than 12,000 people would die from the disease. 10 People living with multiple myeloma have a 5-year survival rate of 59.8 percent. 11 While some people diagnosed with multiple myeloma initially have no symptoms, most patients are diagnosed due to symptoms that can include bone fracture or pain, low red blood cell counts, tiredness, high calcium levels and kidney problems or infections. 12,13 TECVAYLI ® IMPORTANT SAFETY INFORMATION INDICATION AND USAGE TECVAYLI ® (teclistamab-cqyv) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). WARNINGS AND PRECAUTIONS Cytokine Release Syndrome - TECVAYLI ® can cause cytokine release syndrome (CRS), including life-threatening or fatal reactions. In the clinical trial, CRS occurred in 72% of patients who received TECVAYLI ® at the recommended dose, with Grade 1 CRS occurring in 50% of patients, Grade 2 in 21%, and Grade 3 in 0.6%. Recurrent CRS occurred in 33% of patients. Most patients experienced CRS following step-up dose 1 (42%), step-up dose 2 (35%), or the initial treatment dose (24%). Less than 3% of patients developed first occurrence of CRS following subsequent doses of TECVAYLI ® . The median time to onset of CRS was 2 (range: 1 to 6) days after the most recent dose with a median duration of 2 (range: 1 to 9) days. Clinical signs and symptoms of CRS included, but were not limited to, fever, hypoxia, chills, hypotension, sinus tachycardia, headache, and elevated liver enzymes (aspartate aminotransferase and alanine aminotransferase elevation). Initiate therapy according to TECVAYLI ® step-up dosing schedule to reduce risk of CRS. Administer pretreatment medications to reduce risk of CRS and monitor patients following administration of TECVAYLI ® accordingly. At the first sign of CRS, immediately evaluate patient for hospitalization. Administer supportive care based on severity and consider further management per current practice guidelines. Withhold or permanently discontinue TECVAYLI ® based on severity. TECVAYLI ® is available only through a restricted program under a REMS. Neurologic Toxicity including ICANS - TECVAYLI ® can cause serious or life-threatening neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). In the clinical trial, neurologic toxicity occurred in 57% of patients who received TECVAYLI ® at the recommended dose, with Grade 3 or 4 neurologic toxicity occurring in 2.4% of patients. The most frequent neurologic toxicities were headache (25%), motor dysfunction (16%), sensory neuropathy (15%), and encephalopathy (13%). With longer follow-up, Grade 4 seizure and fatal Guillain-Barré syndrome (one patient each) occurred in patients who received TECVAYLI ® . In the clinical trial, ICANS was reported in 6% of patients who received TECVAYLI ® at the recommended dose. Recurrent ICANS occurred in 1.8% of patients. Most patients experienced ICANS following step-up dose 1 (1.2%), step-up dose 2 (0.6%), or the initial treatment dose (1.8%). Less than 3% of patients developed first occurrence of ICANS following subsequent doses of TECVAYLI ® . The median time to onset of ICANS was 4 (range: 2 to 8) days after the most recent dose with a median duration of 3 (range: 1 to 20) days. The most frequent clinical manifestations of ICANS reported were confusional state and dysgraphia. The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS. Monitor patients for signs and symptoms of neurologic toxicity during treatment. At the first sign of neurologic toxicity, including ICANS, immediately evaluate patient and provide supportive therapy based on severity. Withhold or permanently discontinue TECVAYLI ® based on severity per recommendations and consider further management per current practice guidelines. Due to the potential for neurologic toxicity, patients are at risk of depressed level of consciousness. Advise patients to refrain from driving or operating heavy or potentially dangerous machinery during and for 48 hours after completion of TECVAYLI ® step-up dosing schedule and in the event of new onset of any neurologic toxicity symptoms until neurologic toxicity resolves. TECVAYLI ® is available only through a restricted program under a REMS. TECVAYLI ® and TALVEY ® REMS - TECVAYLI ® is available only through a restricted program under a REMS called the TECVAYLI ® and TALVEY ® REMS because of the risks of CRS and neurologic toxicity, including ICANS. Hepatotoxicity - TECVAYLI ® can cause hepatotoxicity, including fatalities. In patients who received TECVAYLI ® at the recommended dose in the clinical trial, there was one fatal case of hepatic failure. Elevated aspartate aminotransferase (AST) occurred in 34% of patients, with Grade 3 or 4 elevations in 1.2%. Elevated alanine aminotransferase (ALT) occurred in 28% of patients, with Grade 3 or 4 elevations in 1.8%. Elevated total bilirubin occurred in 6% of patients with Grade 3 or 4 elevations in 0.6%. Liver enzyme elevation can occur with or without concurrent CRS. Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated. Withhold TECVAYLI ® or consider permanent discontinuation of TECVAYLI ® based on severity. Infections - TECVAYLI ® can cause severe, life-threatening, or fatal infections. In patients who received TECVAYLI ® at the recommended dose in the clinical trial, serious infections, including opportunistic infections, occurred in 30% of patients, with Grade 3 or 4 infections in 35%, and fatal infections in 4.2%. Monitor patients for signs and symptoms of infection prior to and during treatment with TECVAYLI ® and treat appropriately. Administer prophylactic antimicrobials according to guidelines. Withhold TECVAYLI ® or consider permanent discontinuation of TECVAYLI ® based on severity. Monitor immunoglobulin levels during treatment with TECVAYLI ® and treat according to guidelines, including infection precautions and antibiotic or antiviral prophylaxis. Neutropenia - TECVAYLI ® can cause neutropenia and febrile neutropenia. In patients who received TECVAYLI ® at the recommended dose in the clinical trial, decreased neutrophils occurred in 84% of patients, with Grade 3 or 4 decreased neutrophils in 56%. Febrile neutropenia occurred in 3% of patients. Monitor complete blood cell counts at baseline and periodically during treatment and provide supportive care per local institutional guidelines. Monitor patients with neutropenia for signs of infection. Withhold TECVAYLI ® based on severity. Hypersensitivity and Other Administration Reactions - TECVAYLI ® can cause both systemic administration-related and local injection-site reactions. Systemic Reactions - In patients who received TECVAYLI ® at the recommended dose in the clinical trial, 1.2% of patients experienced systemic-administration reactions, which included Grade 1 recurrent pyrexia and Grade 1 swollen tongue. Local Reactions - In patients who received TECVAYLI ® at the recommended dose in the clinical trial, injection-site reactions occurred in 35% of patients, with Grade 1 injection-site reactions in 30% and Grade 2 in 4.8%. Withhold TECVAYLI ® or consider permanent discontinuation of TECVAYLI ® based on severity. Embryo-Fetal Toxicity - Based on its mechanism of action, TECVAYLI ® may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with TECVAYLI ® and for 5 months after the last dose. ADVERSE REACTIONS The most common adverse reactions (≥20%) were pyrexia, CRS, musculoskeletal pain, injection site reaction, fatigue, upper respiratory tract infection, nausea, headache, pneumonia, and diarrhea. The most common Grade 3 to 4 laboratory abnormalities (≥20%) were decreased lymphocytes, decreased neutrophils, decreased white blood cells, decreased hemoglobin, and decreased platelets. Please read full Prescribing Information , including Boxed WARNING, for TECVAYLI ® . DARZALEX FASPRO ® INDICATIONS AND IMPORTANT SAFETY INFORMATION INDICATIONS DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) is indicated for the treatment of adult patients with multiple myeloma: In combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant In combination with bortezomib, melphalan, and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant In combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy In combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant In combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor (PI) In combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy In combination with bortezomib and dexamethasone in patients who have received at least one prior therapy As monotherapy in patients who have received at least three prior lines of therapy including a PI and an immunomodulatory agent or who are double refractory to a PI and an immunomodulatory agent IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS DARZALEX FASPRO ® is contraindicated in patients with a history of severe hypersensitivity to daratumumab, hyaluronidase, or any of the components of the formulation. WARNINGS AND PRECAUTIONS Hypersensitivity and Other Administration Reactions Both systemic administration-related reactions, including severe or life-threatening reactions, and local injection-site reactions can occur with DARZALEX FASPRO ® . Fatal reactions have been reported with daratumumab-containing products, including DARZALEX FASPRO ® . Systemic Reactions In a pooled safety population of 1249 patients with multiple myeloma (N=1056) or light chain (AL) amyloidosis (N=193) who received DARZALEX FASPRO ® as monotherapy or in combination, 7% of patients experienced a systemic administration-related reaction (Grade 2: 3.2%, Grade 3: 0.7%, Grade 4: 0.1%). Systemic administration-related reactions occurred in 7% of patients with the first injection, 0.2% with the second injection, and cumulatively 1% with subsequent injections. The median time to onset was 2.9 hours (range: 5 minutes to 3.5 days). Of the 165 systemic administration-related reactions that occurred in 93 patients, 144 (87%) occurred on the day of DARZALEX FASPRO ® administration. Delayed systemic administration-related reactions have occurred in 1% of the patients. Severe reactions included hypoxia, dyspnea, hypertension, tachycardia, and ocular adverse reactions, including choroidal effusion, acute myopia, and acute angle closure glaucoma. Other signs and symptoms of systemic administration-related reactions may include respiratory symptoms, such as bronchospasm, nasal congestion, cough, throat irritation, allergic rhinitis, and wheezing, as well as anaphylactic reaction, pyrexia, chest pain, pruritus, chills, vomiting, nausea, hypotension, and blurred vision. Pre-medicate patients with histamine-1 receptor antagonist, acetaminophen, and corticosteroids. Monitor patients for systemic administration-related reactions, especially following the first and second injections. For anaphylactic reaction or life-threatening (Grade 4) administration-related reactions, immediately and permanently discontinue DARZALEX FASPRO ® . Consider administering corticosteroids and other medications after the administration of DARZALEX FASPRO ® depending on dosing regimen and medical history to minimize the risk of delayed (defined as occurring the day after administration) systemic administration-related reactions. Ocular adverse reactions, including acute myopia and narrowing of the anterior chamber angle due to ciliochoroidal effusions with potential for increased intraocular pressure or glaucoma, have occurred with daratumumab-containing products. If ocular symptoms occur, interrupt DARZALEX FASPRO ® and seek immediate ophthalmologic evaluation prior to restarting DARZALEX FASPRO ® . Local Reactions In this pooled safety population, injection-site reactions occurred in 7% of patients, including Grade 2 reactions in 0.8%. The most frequent (>1%) injection-site reaction was injection-site erythema. These local reactions occurred a median of 5 minutes (range: 0 minutes to 6.5 days) after starting administration of DARZALEX FASPRO ® . Monitor for local reactions and consider symptomatic management. Neutropenia Daratumumab may increase neutropenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Monitor patients with neutropenia for signs of infection. Consider withholding DARZALEX FASPRO ® until recovery of neutrophils. In lower body weight patients receiving DARZALEX FASPRO ® , higher rates of Grade 3-4 neutropenia were observed. Thrombocytopenia Daratumumab may increase thrombocytopenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Consider withholding DARZALEX FASPRO ® until recovery of platelets. Embryo-Fetal Toxicity Based on the mechanism of action, DARZALEX FASPRO ® can cause fetal harm when administered to a pregnant woman. DARZALEX FASPRO ® may cause depletion of fetal immune cells and decreased bone density. Advise pregnant women of the potential risk to a fetus. Advise females with reproductive potential to use effective contraception during treatment with DARZALEX FASPRO ® and for 3 months after the last dose. The combination of DARZALEX FASPRO ® with lenalidomide, thalidomide, or pomalidomide is contraindicated in pregnant women because lenalidomide, thalidomide, and pomalidomide may cause birth defects and death of the unborn child. Refer to the lenalidomide, thalidomide, or pomalidomide prescribing information on use during pregnancy. Interference With Serological Testing Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive indirect antiglobulin test (indirect Coombs test). Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab administration. Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient's serum. The determination of a patient's ABO and Rh blood type are not impacted. Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX FASPRO ® . Type and screen patients prior to starting DARZALEX FASPRO ® . Interference With Determination of Complete Response Daratumumab is a human immunoglobulin G (IgG) kappa monoclonal antibody that can be detected on both the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the clinical monitoring of endogenous M-protein. This interference can impact the determination of complete response and of disease progression in some DARZALEX FASPRO ® -treated patients with IgG kappa myeloma protein. ADVERSE REACTIONS In multiple myeloma, the most common adverse reaction (≥20%) with DARZALEX FASPRO ® monotherapy is upper respiratory tract infection. The most common adverse reactions with combination therapy (≥20% for any combination) include fatigue, nausea, diarrhea, dyspnea, insomnia, headache, pyrexia, cough, muscle spasms, back pain, vomiting, hypertension, upper respiratory tract infection, peripheral sensory neuropathy, constipation, pneumonia, and peripheral edema. The most common hematology laboratory abnormalities (≥40%) with DARZALEX FASPRO ® are decreased leukocytes, decreased lymphocytes, decreased neutrophils, decreased platelets, and decreased hemoglobin. Please click here to see the full Prescribing Information for DARZALEX FASPRO ® . About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com . Follow us at @JanssenUS and @JNJInnovMed . Janssen Research & Development, LLC and Janssen Biotech, Inc. are both Johnson & Johnson companies. Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of TECVAYLI ® (teclistamab-cqyv ) and DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, Janssen Biotech, Inc., and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 , including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. None of Janssen Research & Development, LLC, Janssen Biotech, Inc. nor Johnson & Johnson undertake to update any forward-looking statement as a result of new information or future events or developments. * Marc S. Raab , M.D., has provided consulting, advisory, and speaking services to Johnson & Johnson; he has not been paid for any media work. 1 Raab, Marc, S., et al, 493 Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial. 2024 American Society of Hematology Annual Meeting. December 2024 . 2 Zamagni, Elena, et al., 494 Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the MajesTEC-4/EMN30 Trial. 2024 American Society of Hematology Annual Meeting. December 2024 . 3 GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 (HD10/DSMMXX). https://clinicaltrials.gov/study/NCT05695508 . Accessed November 2024 . 4 Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4). https://clinicaltrials.gov/study/NCT05243797 . Accessed November 2024 . 5 A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7). https://classic.clinicaltrials.gov/ct2/show/NCT05552222 . Accessed November 2024 . 6 U.S. FDA Approves TECVAYLI ® (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. https://www.jnj.com/u-s-fda-approves-tecvayli-teclistamab-cqyv-the-first-bispecific-t-cell-engager-antibody-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma . Accessed November 2024 . 7 Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548-5672020;95(5):548-567. http://www.ncbi.nlm.nih.gov/pubmed/32212178 8 National Cancer Institute. Plasma Cell Neoplasms. https://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq . Accessed November 2024 . 9 City of Hope. Multiple Myeloma: Causes, Symptoms & Treatments. https://www.cancercenter.com/cancer-types/multiple-myeloma . Accessed November 2024 . 10 American Cancer Society. Key Statistics About Multiple Myeloma. https://www.cancer.org/cancer/multiple-myeloma/about/key-statistics.html#:~:text=Multiple%20myeloma%20is%20a%20relatively,men%20and%2015%2C370%20in%20women . Accessed November 2024 . 11 SEER Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute. https://seer.cancer.gov/explorer/ . Accessed November 2024 . 12 American Cancer Society. What is Multiple Myeloma? https://www.cancer.org/cancer/multiple-myeloma/about/what-is-multiple-myeloma.html . Accessed November 2024 . 13 American Cancer Society. Multiple Myeloma Early Detection, Diagnosis, and Staging. https://www.cancer.org/cancer/types/multiple-myeloma/detection-diagnosis-staging/detection.html . Accessed November 2024 . SOURCE Johnson & JohnsonTweet Facebook Mail Donald Trump has pushed Russian leader Vladimir Putin to act to reach an immediate cease-fire with Ukraine, describing it as part of his active efforts as US president-elect to end the war despite being weeks from taking office. "Zelensky and Ukraine would like to make a deal," Trump wrote on social media, referring to Ukraine's president, Volodymyr Zelenskyy. In a television interview that aired Sunday, Trump also said he would be open to reducing military aid to Ukraine and pulling the United States out of NATO. Those are two threats that have alarmed Ukraine, NATO allies and many in the US national security community. READ MORE: Syrian government falls, ending 50 years of iron rule by one family  French President Emmanuel Macron, centre, poses with US President-elect Donald Trump, left, and Ukraine President Volodymyr Zelenskyy at the Elysee Palace. (AP) Asked on NBC's "Meet the Press" if he were actively working to end the nearly three-year-old Ukraine war, Trump said, "I am." He refused to say if he had spoken to Putin since winning the election in November. "I don't want to say anything about that, because I don't want to do anything that could impede the negotiation," Trump said. Trump's call for an immediate cease-fire went beyond the public policy stands taken by both the Biden administration and Ukraine and drew a cautious response from Zelenskyy. It also marked Trump's wading unusually deeply into efforts before his inauguration on January 20, 2025, to resolve one of the major global crises facing the lame-duck Biden administration. Trump made his proposal after a weekend meeting in Paris with French and Ukrainian leaders in Paris, where many world leaders gathered to celebrate the restoration of Notre Dame cathedral after a devastating fire. Of his advisers that traveled with him, none appeared to have expertise on Ukraine. READ MORE: FBI offers $50k reward in hunt for the gunman who killed UnitedHealthcare CEO  Ukraine reacted to Trump's call for a ceasefire with caution. (AP) Kyiv would like to close a deal and "stop the madness," Trump wrote on his social media platform Truth Social. "There should be an immediate ceasefire and negotiations should begin." "I know Vladimir well. This is his time to act. China can help. The World is waiting!" Trump added. He was referring to mediation efforts by China that many in the West have seen as favouring Russia. Zelenskyy described his discussions Saturday with Trump, brought together by French President Emmanuel Macron, as "constructive" but has given no further details. In a post Sunday on the Telegram messaging app, Zelenskyy cautioned that Ukraine needs a "just and robust peace, that Russians will not destroy within a few years." READ MORE: Suspected underground explosion rocks busy Gold Coast street  There are fears a ceasefire would favour Vladimir Putin. (AP) "When we talk about an effective peace with Russia, we must talk first of all about effective peace guarantees. Ukrainians want peace more than anyone else. Russia brought war to our land," Zelenskyy said. Kremlin spokesman Dmitry Peskov responded to Trump's post by repeating Moscow's longstanding message that it is open to talks with Ukraine. Peskov referenced a decree by Zelenskyy from October 2022 that formally declared the prospect of any talks "impossible" as long as Putin was Russia's leader. That decree came after Putin proclaimed four occupied regions of Ukraine to be part of Russia, in what Kyiv and the West said was a clear violation of Ukrainian sovereignty. Trump's former national security adviser, retired Lieutenant General HR McMaster, warned there was no such thing as a quick fix to ending Russia's war with Ukraine. "What I'm worried about is this kind of flawed idea that Putin can be placated, right, that Putin will come to some kind of a deal," McMaster told "Fox News Sunday." US President Joe Biden has pushed aid for Ukraine. (Alex Wong/Getty Images) "I think it's really important for President Trump to adhere to his instinct in this connection ... peace through strength," McMaster said, adding, "How about give them what they need to defend themselves, and then saying to Putin, 'You're going to lose this war?'" While Trump has said before that he would like to see a quick cease-fire in Ukraine, his proposal Sunday was framed as a direct appeal to Russia. The quick responses from Ukraine and Russia demonstrated the seriousness with which they regarded the idea from the incoming American president. Both Trump and the Biden administration officials have pointed to Russia's disengagement in Syria, where the Russian military largely moved out of the way in recent days as Syrian rebels overthrew the country's Russian-allied president, as evidence of the way the Ukraine was has sapped Russia's resources. The Biden administration and other supporters of Ukraine have made a point of not being seen to press Ukraine for an immediate truce. Ukraine's allies fear a quick deal would be largely on the terms of its more powerful neighbor, potentially forcing damaging concessions on Ukraine and allowing Russia to resume the war again once it has built back up its military strength. Ukraine defenders 'bending but not breaking' in fierce fighting View Gallery For most of the war, Kyiv's official position has been to call for a full withdrawal of Russian troops from internationally recognised Ukrainian territory, including Crimea, as a condition for peace talks. Moscow, too, has demanded heavy concessions from Ukraine as a condition for even beginning talks. Trump portrays himself as up to making fast deals to resolve conflicts in Ukraine and the Middle East that have frustrated many of the Biden administration's own mediation efforts. There is no prohibition on incoming officials or nominees meeting with foreign officials, and it is common and fine for them to do so — unless those meetings are designed to subvert or otherwise affect current US policy. The Logan Act bars private citizens from trying to intervene in "disputes or controversies" between the United States and foreign powers without government approval. But the 1799 statute has produced just two criminal cases, none since the 1850s and neither resulting in a criminal conviction. In the NBC interview that was taped Friday, Trump renewed his warning to NATO allies that he did not see continued US participation in the Western military alliance as a given during his second term. Trump has long complained that European and the Canadian governments in the mutual-defence bloc are freeloading on military spending by the US, by far the most powerful partner in NATO. NATO and its member governments say a majority of countries in the bloc are now hitting voluntary targets for military spending, due in part to pressure from Trump in his first term. Asked whether he would consider the possibility of pulling out of NATO, Trump indicated that was an open question. "If they're paying their bills, and if I think they're treating us fairly, the answer is absolutely I'd stay with NATO," he said. But if not, he was asked if he would consider pulling the US out of the alliance. Trump responded, "Absolutely. Yeah, absolutely." Trump expressed the same openness when asked if Ukraine should brace for possible cuts in US aid after Trump moves into the White House. "Possibly," he said. US arms and other military support are vital to Ukraine's efforts to fend off invading Russian forces, and Democratic President Joe Biden has been surging assistance to Ukraine ahead of leaving office. Defense Secretary Lloyd Austin on Saturday announced nearly US$1 billion ($1.57 billion) more in longer-term weapons support to Ukraine. DOWNLOAD THE 9NEWS APP : Stay across all the latest in breaking news, sport, politics and the weather via our news app and get notifications sent straight to your smartphone. Available on the Apple App Store and Google Play .

Hyderabad: Laurus Bio, a subsidiary of Hyderabad-based biopharma player Laurus Labs Ltd, has secured an equity investment of Rs 120 crore from Eight Roads Ventures and F-Prime Capital. Laurus Labs informed the bourses on Friday that its subsidiary has inked a definite agreement for the investment round that will also see Laurus Labs co-invest Rs 40 crore at the same valuation. The company stated that the promoters of Laurus Bio were also issued share warrants, exercisable up to two years from the date of issue at the same valuation. "Laurus Labs or Eight Roads Ventures have the right to invest up to an additional amount of Rs 35 crore before December 2025 at the same valuation. Upon completion of the transaction, Laurus Labs, Eight Roads Ventures, and the promoters of Laurus Bio will hold 75%, 14%, and 9% stake, respectively, on a fully diluted basis," Laurus Labs said in a regulatory filing. The company said the funds raised will be utilised by Laurus Bio for further expansion of its fermentation-based manufacturing capabilities to cater to the growing customer demand. Laurus Labs founder & CEO Dr Satyanarayana Chava and Laurus Bio CEO Rajesh Krishnamurthy said the fundraise will drive the expansion of the manufacturing and R&D infrastructure of Laurus Bio and enable it to further accelerate growth opportunities. "This investment will enable the company to further expand and accelerate microbial-fermentation capabilities, including faster development of new products, speeding up the internal pipeline, enhancing high-quality commercial-scale capacity to partners, and growing our industry position," Dr Chava said. Eight Roads Ventures India managing partner Dr Prem Pavoor said Laurus Labs and Laurus Bio (formerly Richcore Lifesciences) built a best-in-class biomanufacturing platform to cater to the growing global demand for sustainable manufacturing technologies. "Biomanufacturing is already being utilised across a range of industries including personal care, materials, food and nutrition, and pharmaceuticals. We are looking forward to growing Laurus Bio into a global leader in this emerging segment," Dr Pavoor said. Stay updated with the latest news on Times of India . Don't miss daily games like Crossword , Sudoku , and Mini Crossword .

SMU feeling good heading into ACC opener against VirginiaAston Villa had a stoppage-time goal disallowed as they drew 0-0 with Juventus in the Champions League. Morgan Rogers looked to have given Unai Emery’s side another famous win when he slammed a loose ball home at the death, but referee Jesus Gil Manzano ruled Diego Carlos to have fouled Juve goalkeeper Michele Di Gregorio and the goal was chalked off. It was a disappointment for Villa, who remain unbeaten at home in their debut Champions League campaign and are still in contention to qualify automatically for the last 16. A very controversial finish at Villa Park 😲 Morgan Rogers' late goal is ruled out for a foul on Juventus goalkeeper Michele Di Gregorio and the match ends 0-0 ❌ 📺 @tntsports & @discoveryplusUK pic.twitter.com/MyYL5Vdy3r — Football on TNT Sports (@footballontnt) November 27, 2024 Emiliano Martinez had earlier displayed why he was named the best goalkeeper in the world as his wonder save kept his side level in the second half. The Argentina international paraded his two Yashin Trophies on the pitch before kick-off at Villa Park and then showed why he won back-to-back FIFA awards when he denied Francisco Conceicao. Before Rogers’ moment of drama in the fourth minute of added time, the closest Villa came to scoring was in the first half when Lucas Digne’s free-kick hit the crossbar. But a draw was a fair result which leaves Villa out of the top eight on goal difference and Juventus down in 19th. Before the game Emery called Juventus one of the “best teams in the world, historically and now”, but this was an Italian side down to the bare bones. Only 14 outfield players made the trip from Turin, with striker Dusan Vlahovic among those who stayed behind. The opening 30 minutes were forgettable before the game opened up. Ollie Watkins, still chasing his first Champions League goal, had Villa’s first presentable chance as he lashed an effort straight at Di Gregorio. Matty Cash then had a vicious effort from the resulting corner which was blocked by Federico Gatti and started a counter-attack which ended in Juventus striker Timothy Weah. Villa came closest to breaking the deadlock at the end of the first half when Digne’s 20-yard free-kick clipped the top of the crossbar and went over. Martinez then produced his brilliant save just after the hour. A corner made its way through to the far post where Conceicao was primed to head in at the far post, but Martinez sprawled himself across goal to scoop the ball away. How has he kept that one out?! 🤯 Emi Martinez with an INCREDIBLE save to keep it goalless at Villa Park ⛔️ 📺 @tntsports & @discoveryplusUK pic.twitter.com/OkcWHB7YIk — Football on TNT Sports (@footballontnt) November 27, 2024 Replays showed most of the ball went over the line, but the Argentinian got there with millimetres to spare. At the other end another fine goal-line block denied John McGinn as Manuel Locatelli got his foot in the way with Di Gregorio beaten. The game looked to be petering out until a last-gasp free-kick saw Rogers slam home, but whistle-happy official Gil Manzano halted the celebrations by ruling the goal out. We do not moderate comments, but we expect readers to adhere to certain rules in the interests of open and accountable debate.

"To everyone who supported this campaign–volunteering, encouraging, and sharing our message–thank you from the bottom of my heart," De Serpa wrote in the letter. "This campaign succeeded because of you. I hope many of you will continue to advise and guide me in the years ahead. Your support and inspiration will remain key as we move forward together."Golden State Warriors @ Denver Nuggets Current Records: Golden State 12-7, Denver 10-8 When: Tuesday, December 3, 2024 at 10 p.m. ET Where: Ball Arena -- Denver, Colorado TV: TNT Follow: CBS Sports App Ticket Cost: $40.00 The Warriors are 2-8 against the Nuggets since April of 2022 but they'll have a chance to close the gap a little bit on Tuesday. The Golden State Warriors will challenge the Denver Nuggets at 10:00 p.m. ET at Ball Arena. The Warriors are expected to lose this one by 4.5 points, so we'll see if that gives them a bit of motivation. The Warriors are headed into Tuesday's contest looking for a big change in momentum after dropping their fourth straight game on Saturday. They took a 113-105 hit to the loss column at the hands of the Suns. Meanwhile, the Nuggets' game on Sunday was all tied up 59-59 at the half, but sadly for them it didn't stay that way. They took a 126-122 hit to the loss column at the hands of the Clippers. Denver didn't live up to their potential and found themselves falling short of the advantage oddsmakers thought they had coming into the game. The Nuggets' loss came about despite a quality game from Nikola Jokic, who dropped a triple-double on 28 points, 14 rebounds, and 11 assists. Even though they lost, the Nuggets were working as a unit and finished the game with 37 assists (they're ranked second in assists per game overall). They easily outclassed their opponents in that department as the Clippers only posted 28. Golden State's defeat dropped their record down to 12-7. As for Denver, their loss ended a three-game streak of away wins and brought them to 10-8. The Warriors ended up a good deal behind the Nuggets in their previous meeting back in February, losing 119-103. A big factor in that loss was the dominant performance of Jokic, who dropped a triple-double on 32 points, 16 rebounds, and 16 assists. Back with a vengeance, will the Warriors be able to stop him this time around? There's only one way to find out. Denver is a 4.5-point favorite against Golden State, according to the latest NBA odds . The line has drifted a bit towards the Nuggets, as the game opened with the Nuggets as a 2.5-point favorite. The over/under is 239 points. See NBA picks for every single game, including this one, from SportsLine's advanced computer model. Get picks now . Denver has won 8 out of their last 10 games against Golden State. Feb 25, 2024 - Denver 119 vs. Golden State 103 Jan 04, 2024 - Denver 130 vs. Golden State 127 Dec 25, 2023 - Denver 120 vs. Golden State 114 Nov 08, 2023 - Denver 108 vs. Golden State 105 Apr 02, 2023 - Denver 112 vs. Golden State 110 Feb 02, 2023 - Denver 134 vs. Golden State 117 Oct 21, 2022 - Denver 128 vs. Golden State 123 Apr 27, 2022 - Golden State 102 vs. Denver 98 Apr 24, 2022 - Denver 126 vs. Golden State 121 Apr 21, 2022 - Golden State 118 vs. Denver 113

By KATE BRUMBACK ATLANTA (AP) — A judge is weighing whether a Georgia state Senate committee has the right to subpoena testimony and documents from Fulton County District Attorney Fani Willis as it looks into whether she has engaged in misconduct during her prosecution of President-elect Donald Trump. The Republican-led committee sent subpoenas to Willis in August seeking to compel her to testify at its September meeting and to produce scores of documents. The committee was formed earlier this year to examine allegations of “various forms of misconduct” by Willis, an elected Democrat, during her prosecution of Trump and others over their efforts to overturn the former president’s 2020 election loss in Georgia. Willis’ attorney, former Democratic Gov. Roy Barnes, told Fulton County Superior Court Judge Shukura Ingram during a hearing Tuesday that although the Georgia General Assembly has subpoena power, that power is not automatically conferred on a single legislative chamber or its committees. Even if the committee did have such power, he argued, the subpoenas in question are overly broad and not related to a legitimate legislative need. Barnes said the focus on Willis and her investigation into Trump shows that the committee was politically motivated and not a legitimate inquiry into the practices of district attorneys’ offices: “What they were trying to do is chill the prosecution of Donald Trump and find out what they had.” Josh Belinfante, a lawyer representing the lawmakers, said there is nothing in the Georgia Constitution that prohibits the Senate from issuing a subpoena. The duly formed interim committee is looking into whether new legislation is needed to regulate the practices of district attorneys’ offices in the state, he argued. “They are investigating and making an inquiry into these allegations that may show that existing state laws, including those establishing the processes for selecting, hiring and compensating special assistant district attorneys, are inadequate,” Belinfante said. The resolution creating the committee focused in particular on Willis’ hiring of special prosecutor Nathan Wade , with whom she had a romantic relationship , to lead the prosecution against Trump and others. It says the relationship amounted to a “clear conflict of interest and a fraud upon the taxpayers” of the county and state. One of the committee’s subpoenas orders Wills to produce documents related to Wade, including documents related to his hiring and payment, documents related to money or items of value that Wade and Willis may have exchanged, text messages and emails between the two, and their phone records. The committee also requested any documents her office sent in response to requests from the U.S. House, as well as communications Willis and her office had with the White House, the U.S. Justice Department and the House relating to the 2020 presidential election. And they asked for documents related to federal grant money Willis’ office has received. Before the deadlines in the subpoenas, Willis challenged them in court. Willis’ challenge was pending in mid-September when she skipped a hearing during which the committee members had hoped to question her. In October, the committee asked Ingram to require Willis to comply with the subpoenas. The committee’s lawyers wrote in a court filing that Willis’ failure to do so had delayed its ability to finish its inquiry and to provide recommendations for any legislation or changes in appropriations that might result. Barnes also argued that once the regular legislative session has adjourned, which happened in March this year, legislative committees can meet to study issues and come up with recommendations but do not have the power to compel someone to appear or produce documents. Belinfante rejected that, saying the state Constitution expressly permits the creation of interim committees and allows them to make their rules. Even if these subpoenas were validly issued, Barnes argued, they ask for too much, including private and personal information that is not a legitimate target of a legislative subpoena. Related Articles National News | Are you a former SmileDirectClub customer? You might be eligible for a refund National News | Justice Department announces sweeping reforms to curb suicides in federal prisons and jails National News | Defense makes closing argument in murder trial of Cash App founder Bob Lee National News | A judge has once again rejected Musk’s multi-billion-dollar Tesla pay package. Now what? National News | Is Enron back? If it’s a joke, some former employees aren’t laughing Belinfante said the lawmakers are simply trying to do their jobs. He asked that Willis be ordered to appear before the committee in early January. He also asked that she be ordered to provide the requested documents and explain what privilege justifies any that are excluded. With a glaring lack of state case law on the issue of the General Assembly’s subpoena power, that’s one issue Ingram will have to address. She said she will consider the arguments and release her order as soon as she can. Willis and Wade have acknowledged that they had a relationship but have said it began after he was hired and ended before the indictment against Trump was filed. Trump and other defendants argued that the relationship created a conflict of interest that should disqualify Willis and her office from continuing with her prosecution of the case. Fulton County Superior Court Judge Scott McAfee ruled in March that Willis’ actions showed a “tremendous lapse in judgment,” but he did not find a conflict of interest that would disqualify Willis. He said she could continue her prosecution as long as Wade stepped aside, which he did. Trump and others have appealed that ruling to the Georgia Court of Appeals, and that appeal remains pending.